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Abstract
Electronic health record (EHR) data are becoming an increasingly common data
source for understanding clinical risk of acute events. While their longitudinal nature
presents opportunities to observe changing risk over time, these analyses are compli-
cated by the sparse and irregular measurements of many of the clinical metrics making
typical statistical methods unsuitable for these data. In this paper, we present an
analytic procedure to both sample from an EHR and analyze the data to detect clin-
ically meaningful markers of acute myocardial infarction (MI). Using an EHR from
a large national dialysis organization we abstracted the records of 64,318 individuals
and identified 5,314 people that had an MI during the study period. We describe a
nested case-control design to sample appropriate controls and an analytic approach
using regression splines. Fitting a mixed-model with truncated power splines we per-
form a series of goodness-of-fit tests to determine whether any of 11 regularly collected
laboratory markers are useful clinical predictors. We test the clinical utility of each
marker using an independent test set. The results suggest that EHR data can be easily
used to detect markers of clinically acute events. Special software or analytic tools are
not needed, even with irregular EHR data.
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1 Introduction
Electronic health records (EHRs) constitute a relatively new data source that are being
used to understand and predict near-term clinical events (Goldstein et al., 2014). They
are characterized by having dense, serial information on patients receiving clinical care,
allowing for a granular view of a patient’s evolving health status. A National Heart Lung
and Blood Institute working group recently prioritized the assessment of near term risk
of acute cardiac events (Eagle et al., 2010). Specifically the group focused on the use of
biomarkers to make such assessments.
Before developing predictive models, it is first necessary to detect potentially useful
markers. If the biomarker were measured once, a typical approach to detect such markers
would be to perform a logistic regression, regressing the probability of an event onto the
marker and other covariates, such as:
logit(P (Cardiac Event)) = α+ β1Marker + βWCovariates (1)
where β1 would be the parameter of interest, representing whether changes in the marker
change the probability of the event of interest. Of course, one of the key advantages of EHR
data is that markers are measured over time. While this allows for a more sophisticated
view of changes it also makes the analysis more challenging. The analysis can be simplified
by averaging or summarizing laboratory values across time but this may result in a loss of
information. Instead we ideally want to consider variation in the marker over time. We
can reform model (1) as:
logit(P (Cardiac Event)) = α+
∫
β1(t)Marker(t)dt+ βWCovariates (2)
where now we are integrating over multiple time points, t. To fit such a model we can
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consider discretizing time, however, depending on the number of time points, this may
result in a very high dimensional model. Complicating matters further is that EHR mea-
sures are taken irregularly and sometimes sporadically, meaning patients generally do not
have laboratory measures at comparable time points and frequencies. This makes standard
analytic techniques, which often require well aligned measurements, challenging.
The difficulty of estimating model (2) is reflected in the complex theoretical work and
software that others have developed to fit it (Gertheiss et al., 2013; James, 2002; Yao et
al., 2005). James used a two-stage errors in variable model with cubic splines to estimate
individual curves where the dimension of the spline is larger than the observed observations.
Gertheiss et al. took a modified imputation approach to get measurements on the same
time scale. Yao et al. utilized functional PCA to estimate the curves. Furthermore,
while analyses of the form of model (2) have appeal from a predictive standpoint, they
do not necessarily address the specific question of interest: namely is a given measure a
clinically useful biomarker of an impending event. Another way of phrasing that question
is: does a given laboratory measure show different and detectable patterns among those
that experience an event?
With this question in mind, we suggest a relatively straightforward solution to detecting
clinically useful biomarkers. The model we propose is flexible enough to not only answer
a series of questions about the utility of a laboratory measure to serve as a predictive
marker, but also to allow for the detection of these relationships using established statistical
methods. We illustrate this approach using EHR data from patients with end stage renal
disease (ESRD) undergoing hemodialysis (HD). Patients undergoing outpatient HD are at
increased risk of cardiac events, particularly myocardial infarction (MI). Cardiac disease
accounts for 43% of all cause mortality with approximately 20% due to MI (Herzog, 1999).
Moreover, patients receiving outpatient HD typically have routine and regularly scheduled
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monitoring of several laboratory values for months or years at a time. Therefore, patients
undergoing HD represent an ideal population to study the role of repeated laboratory
measures in the detection of an impending MI.
The rest of the paper is arranged as follows: in section 2 we describe the available data.
Since one of the challenges in working with EHR data is appropriately selecting an analytic
cohort, we also describe a generally useful sampling design. In section 3 we walk through
our proposed analysis which consists of a series of goodness-of-fit tests. In section 4 we
present the analytic results and conclude in section 5.
2 Data Description & Sample Selection
Working with EHR data presents unique opportunities and challenges. We first note that
EHR data are inherently observational, implying all of the caveats and limitations of non-
experimental data. The primary strength and challenge of EHR data are its longitudinal
nature, with individuals having multiple measurements over time. While presenting the
opportunity to observe changes over time - the primary aspect of the present analysis - this
can become complicated since measurements are often taken irregularly. In some EHRs -
though not the current one - the presence of a measure may serve as a risk indicator itself,
e.g. a patient feeling ill and visiting a doctor, producing a measurement in the EHR.
The first challenge is how to appropriately sample an analytic cohort from the EHR. In
the present study we are interested in identifying potential markers of acute MI. This lends
itself well to a retrospective analysis: identify those people with an MI and observe how
different markers change before the event. The subtler question is who is the comparative
group, i.e. controls. Below we describe the data available, how we define the cases and
more importantly how we sample the controls.
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2.1 Data Source
We used two data sources in the analysis: the United States Renal Data System (USRDS)
and the EHR from DaVita, Inc. The USRDS is a national registry that includes almost all
persons with ESRD (Collins et al., 2013). It is created from medical claims submitted to
Medicare, which is mandated by law to pay for the healthcare of the majority of patients
with ESRD, regardless of the age of patients at the start of their HD treatments. DaVita
Inc. is the second largest chain of outpatient dialysis centers in the country. Their EHR
contains detailed session level information on patient dialysis session, laboratory values,
hemodynamic metrics and more. We used an anonymous crosswalk provided by the USRDS
Coordinating Center to link the two datasets. This was conducted under a Data use
Agreement between the National Institute of Diabetes and Digestive and Kidney Diseases
and one of the authors (WCW).
2.2 Selecting the Sample
One can consider an EHR as analogous to a large prospective cohort where only a small
fraction of the cohort will experience an event, each at different time points. With this
in mind, we describe a sampling approach motivated from nested case-control designs to
sample appropriate controls along with eligible cases (Biesheuvel et al., 2008)
2.2.1 Eligible Sample
Any individual who initiated HD between January 1, 1995 and December 31st 2008 and
was a patient at a DaVita, Inc. dialysis facility between January 1st, 2004 and December
31st 2008 was eligible for study. Using the USRDS payer history file, we retained only
those patients who were aged ≥ 67 at the initiation of dialysis and had at least 2 years
of uninterrupted fee-for-service Medicare coverage before their reported first dialysis (first
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service date). Selecting this subset of individuals has two advantages. First we can observe
the health-care claims and associated diagnoses and procedures before the onset of ESRD.
This provides us with increased confidence that we are detecting an incident MI and not a
claim related to a previous MI. Second, we can be near-certain that all health claims are
recorded at the time of initiation of dialysis, without having to apply an eligibility window.
We excluded all individuals with a history of an MI, defined through the presence of any
of the following ICD-9 codes: 410.** and 412. To be as sensitive as possible, patients with
any inpatient code or outpatient codes were removed from analysis.
2.2.2 Cases
Cases were subjects who developed incident MI between 2004 and 2008 while receiving
ongoing dialysis treatment at DaVita, Inc. We defined a case as “active” if a laboratory
measurement was recorded within 14 days of the qualifying event. Events were identified
from either (a) the presence of an ICD-9 code of 410.** during a hospitalization (positive
predictive value 96.9% (Petersen et al., 1999)) or (b) a primary cause of death being
reported as due to Myocardial Infarction (Code 2 or 23) on the death notification record
to Medicare.
2.2.3 Controls
Sampling of controls is the primary challenge in designing retrospective, longitudinal anal-
yses (Wacholder et al., 1992). For nested case-control designs, we want to sample a control
whenever someone becomes a case. In the EHR setting, there are two potential time do-
mains: calendar time and clinical time, i.e. the time since start of maintenance/chronic
dialysis treatment for ESRD (also called “vintage”). We decided to sample controls based
on calendar time and adjust for vintage. For all cases during a calendar month, an equal
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number of controls were sampled, creating an index date. By design, individuals are eli-
gible to serve as controls earlier in time even if they become a case later. For example, a
patient who was diagnosed with ESRD on 7/1/2006 and had an incident MI on 5/1/2008,
would be eligible to serve as a control during the period preceding the MI. While it is
typical in nested case-control design to sample matched controls we chose not to perform
such matching to avoid the additional complications (Cai and Zheng, 2012), but instead
simply adjusted for covariates.
2.2.4 Sample Split
To assess the proposed procedure, we divided the sample into a training set consisting of
incident events and corresponding controls between 2004 and 2007 and an independent
validation set consisting of incident events and controls within 2008.
2.3 Selecting Variables
2.3.1 Predictors of Interest
Through the DaVita EHR, data were abstracted on 11 regularly collected laboratory mea-
sures: albumin, calcium, CO2, creatinine, ferritin, hemoglobin, iron saturation, phospho-
rous, platelet count, potassium, and white blood cell count. It is important to note that
these laboratory measures are collected per-protocol and not based on a patient’s clinical
characteristics. Table 1 lists the predetermined acceptable ranges and approximate fre-
quency of collection. Any laboratory measures that fell outside these ranges were removed.
In order to analyze changes in laboratory measures over time, laboratory values for up
to 180 days preceding the index data were abstracted. Patients were not required to have
a minimal number of laboratory measures.
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Laboratory Test Frequency Collected Acceptable Range
Albumin ∼ 30 days 0.1 - 6 g/dL
Calcium ∼ 7 days 5 - 20 mg/dL
CO2 ∼ 30 days 2 - 50 meq/L
Creatinine ∼ 30 days 0.1 - 30 mg/dL
Ferritin ∼ 90 days 0 - 10000 ng/mL
Hemoglobin ∼ 7 days 2 - 20 g/dL
Iron Transferring Saturation ∼ 30 days 0 - 100%
Phosphorous ∼ 7 days 0.5 - 20 mg/dL
Platelet Count ∼ 30 days 0 - 5000 1000/µL
Potassium ∼ 30 days 1 - 9 meq/L
White Blood Cell Count ∼ 30 days 0 - 100 1000/µL
Table 1: Frequency of collection and acceptable ranges for laboratory tests assessed.
2.3.2 Covariates
Since we are not interested in estimating the direct association of the given laboratory
measure but simply its utility as a biomarker, a minimal number of covariates were included
in the analysis. Specifically, analyses were adjusted for patients age at time of ESRD,
gender, race (Caucasian, African American, Hispanic, Asian and other), and vintage (time
since ESRD).
3 Analytic Approach
3.1 The Statistical Model
The goal of this study is to present a means of detecting clinically relevant laboratory
markers of an impending clinical event. Therefore, in contrast to model (2) we are not
interested in estimating the probability of MI given a sequence of laboratory measures, but
instead modelling how the sequence of laboratory measures may differ between cases and
controls. We consider that person i has ni measurements of a given laboratory measure,
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at times ti1, ti2, . . . tini . We can fit a general model of the form:
Lab(t) = α+ 1MIβ1 + 1MIf(t) + 11−MIf∗(t) +W (t)βW +  (3)
The outcome variable is the laboratory measure, measured at multiple time points t. 1MI
is an indicator for whether the person has an MI with 11−MI the complement (i.e. case
or control). f represents a general function to flexibly estimate changes in laboratory
measures over time. Therefore cases and controls are allowed to have different patterns
over time. Finally, additional covariates (potentially time varying) are represented by W .
The primary analytic question is how to represent the function, f . Following the work
of others we use regression splines, using a q-dimensional vector of basis functions s(t), and
hence f(t) = s(t)′γ. In our representation s(t) is specified using k = q−1 knots. s(t) would
be evaluated ni times, filling the rows of a ni × q basis matrix, where ni is the number
of observed laboratory measurements as above. These are produced for each person, and
combined into an overall spline model matrix. To fit the model we estimate the parameter
vector γ, a q-dimensional coefficient vector. Different spline formulations can be used, we
consider truncated cubic power splines with basis functions:
(t, {(t− ξk)3+}K1 }
evaluated at each knot, ξk. We note the lack of intercept. While natural splines are more
commonly used over truncated power splines, the truncated power spline basis has the
advantage of being linear to the left of the leftmost boundary knot while non-linear to the
right. This is a feature we exploit below. We placed K = 5 knots at, 150, 90, 60, 30, 14
days prior to the index date. By placing more knots closer to the index date we are able
to capture more subtle changes directly prior to that date. Therefore the final model is:
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Labij = αi + 1MIiβ1 + S
′(tij)γ +
(
1MIi × S′(tij)
)
γ∗ +WijβW + ij (4)
Here we have indexed by person i for record j. Each individual has multiple observations
so we include a random intercept, αi. Since 1MIi is an indicator function, the spline basis
for the controls is represented by S′(tij)γ and the basis for the cases S′(tij)γ + S′(tij)γ∗,
allowing for two separate functional representations for cases and controls. Model (4)
is easily estimated as a linear regression with a random intercept, a spline basis for the
timing of the laboratory measurements, and an interaction term between the spline basis
and case-control status.
3.2 Criterion for Clinically Meaningful Differences
Using model (4) as a general form, we conduct a series of goodness of fit tests to assess a
set of clinical questions. To motivate these criterion we consider the prospective scenario
where one is tracking a patient’s laboratory measure over time and wants to determine
whether the pattern indicates a risk of MI. Therefore the goal of the analysis is to detect
those laboratory measures that can be so used.
The first question is whether the trajectory of laboratory values differs between cases
and controls. For this assessment the primary parameter of interest is the vector γ∗, which
represents the difference between the curves for those that experience an MI compared to
those that do not. To formally test whether the two curves are different we perform a
likelihood ratio test comparing the full model to a nested model that does not contain γ∗,
i.e. a model where the only difference in laboratory measures between those that experience
an MI and those that do not is represented as a shift through β1. A rejection of the null
hypothesis that the fits are equivalent, indicates that the laboratory measures differ over
time between cases and controls.
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A second consideration is the trajectory of a marker over time. Specifically, for a
measure to have clinical utility, we would expect that those not experiencing an event
(controls) should present predictable and stable patterns. Conversely, the values among
those about to experience an event (cases) should show a deviation from this stable pattern.
While we could hypothesize various “stable” patterns, for simplicity we consider linearity
to imply stability. Therefore, the laboratory measures for controls should be linear and
for cases non-linear (i.e. curved). To assess this, we can fit model (4) among cases and
controls separately. Therefore β1 and γ
∗ are removed from the model and the parameter
of interest is the spline vector γ:
Labij = αi + S
′(tij)γ +WijβW + ij (5)
This fit is compared to a reduced model that only includes a linear term for time. To call a
laboratory measure a potentially good marker we want to reject the null hypothesis among
the cases and fail to reject the null hypothesis among the controls, i.e. cases should be
non-linear and controls should be linear.
This establishes three criterion to declare a laboratory marker clinically useful:
1. The patterns over time should be different between cases and controls
2. Cases should show non-linearity over time
3. Controls should be linear over time
For each of the laboratory tests we considered a p-value less than 0.05 to indicate sig-
nificance and performed a Bonferroni correction across the set of three tests. This was
repeated separately for each of the 11 markers.
Among the laboratory measures that passed these criterion, a second question of interest
is: how long before an event can changes be detected? We note that truncated power
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splines are linear to the left of the left-most (earliest in time) knot. We illustrate this
concept using simulated toy data in Figure 1. We are fitting a non-linear function (in
black) placing successive knots along the x-axis. We note, that to the left of the first knot
(indicated by a dashed line) the estimated fit is linear.
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Figure 1: Truncated power splines with different knot placements. The dashed line corre-
sponds to the placement of the first (left-most) knot for the same colored line. We note
that to the left of the first knot, the fit is linear. The black line shows the true function,
with the dots the realized data.
Using this property, we can consider the optimal placement of the first knot to be the point
at which the laboratory measures are linear before, i.e. do not change over time. This can
give us an indication as to when a laboratory measure for those that will experience an
event begins to change.
To assess this, we fit a series of models of the form of model (5) among those that
experience the event. We started with a simple linear model. Next we added a knot at 14
days before the event. Then we fit a third model adding a knot at 14 and 28 day before
the event, etc. until we had a model with 12 knots up to 168 days. While we could have
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used a likelihood ratio tests to pick the optimal fit we ultimately did not view this as a
specific hypothesis test and instead chose the model with the minimal AIC as the one with
the best fit.
Finally, we visually inspected the fits from model (4) for each laboratory measure. We
calculated and plotted predicted values for laboratory measures over time with pointwise
95% confidence bands.
3.3 Assessment
As discussed, modifications to model (2) have been proposed to directly estimate the
probability of an event given a vector of time varying measures. However, few have been
implemented in regularly available software. We fit the procedure of Goldsmith et al. (2009)
as applied in the refund package in R. Using the independent confirmatory set (data from
2008), we calculated the probability of MI for each individual based on the 11 separate
laboratory measures. We estimated each models discrimination by calculating the area
under the ROC curve (c-statistic). We considered the marker to be “validated” if there
was a significant improvement in ROC (p < 0.05) upon inclusion of the laboratory measure
to a model containing only demographic factors.
All analyses were performed in R 3.0.1 using the lme4 packages to calculate the mixed
models, and our own function to calculate the truncated power spline basis (see Appendix).
4 Results
A total of 64,318 people were available for study between 2004 to 2008. After removal
of individuals with a history of MI (Figure 1), we abstracted 3,677 individuals with an
incident MI between 2004 and 2007 and additional 1,092 individuals with an incident MI
in 2008 to serve as a validation set. An equal number of controls were selected during
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the same time period. There were similarities between those experiencing events in age
and gender but meaningful differences in regards to race (Table 2). Those experiencing an
event tended to have spent less time on dialysis.
  
4,769 (76%) Active 
DaVita Patient:
3,677 2004-2007
1,092 2008
6,237 (16%) Incident 
MI 2004-2008
39,363 (82%)
without MI prior to joining
DaVita (2004 - 2008)
47,989 (75%) patients 
without MI prior 
to Dialysis
64,318 DaVita patients 
in the EHR
4,769 Controls Sampled
Figure 2: Cohort Selection
Using model (4) described above we estimated the differences in trends of laboratory
measures among those that experienced an MI and those that did not. A likelihood ratio
test with a Bonferroni correction was performed to test whether the two curves differed
(Table 3). Overall, 6 of the 11 tests showed significant differences between those that
experienced an MI and those that did not. In our second analysis, we assessed whether
the 11 markers are linear over time among those that ultimately have an MI and those
that do not. Using model (5) we again performed a likelihood ratio test comparing nested
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MI No MI P-Value
Sample Size 4769 4769
Age at Start of Dialysis 75 (71, 80) 75 (71,79) < 0.001
Gender (Male) 2319 (50%) 2380 (50%) 0.22
Race 0.022
Caucasian 3414 (72%) 3311 (69%)
African American 1152 (24%) 1285 (27%)
Hispanic 136 (3%) 115 (2%)
Asian 50 (1%) 41 (1%)
Other/Unknown 17 (< 1%) 17 (< 1%)
Days on Dialysis 533 (188, 1,088) 553 (245, 1,081) < 0.001
Table 2: Demographics of sampled data.
models. This resulted in five laboratory measures that were clinically useful based on our
predefined criterion of significance.
Among the five laboratory measures that met all three of the above criteria we examined
the point at which the laboratory measures for those experiencing an MI began to depart
from linearity. A series of models were fit, with each one adding an additional knot over
time. The model with the minimal AIC was chosen as the best fit. Table 3 also shows the
optimal fit for each of the five laboratory measures. Albumin, hemoglobin and platelet-
count showed optimal departure within 4 weeks of the event, suggesting that changes could
be detected one-month before an event occurs.
We visually inspected the patterns of change for each of the 11 markers (Figure 3(a-
k)). Using the estimates from model (4) we predicted the laboratory measure for a person
about to experience an MI and a similar control, with 95% point-wise prediction intervals.
Visual inspection confirms the analytic results. Of the laboratory measures that were
not identified as useful markers, all but ferritin, did not visually show differences between
those about to experience and MI and those who did not. Most of the successful laboratory
markers showed departures from linearity immediately preceding the MI, as suggested by
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LRT LRT LRT
Lab Test Overall Among Cases Among Controls Optimal Fit C-Statistic
Albumina < 0.001 < 0.001 0.236 28 Days 0.635b
Calcium 0.243 0.644 0.437 — 0.551
CO2 0.293 1.000 0.469 — 0.547
Creatinine < 0.001 0.246 0.740 — 0.546
Ferritin 0.396 0.021 1.000 — 0.550
Hemoglobina < 0.001 < 0.001 0.585 28 Days 0.591b
Iron Transferring Saturationa < 0.001 0.001 1.000 168 Days 0.572b
Phosphorous 0.361 0.002 1.000 — 0.546
Platelet Counta < 0.001 0.027 0.192 14 Days 0.556
Potassium 1.000 0.459 1.000 — 0.541
White Blood Cell Counta < 0.001 < 0.001 0.926 56 Days 0.588b
Table 3: The first three columns show Bonferroni corrected p-values (across three tests) for each
of the tested metrics. For those labs that met the above criteria we assessed at what point the
cases differentiated themselves from the controls. Using the validation data the c-statistic for
predicting MI.
aMet all three analytic criterion.
bC-statistic shows significant (p < 0.05) improvement over model with just demographic factors (c = 0.541).
analysis 3. The one exception was iron saturation which visually appears to have it’s
greatest departure at about 14 days but analytically was identified at 168 days.
Finally, we assessed the predictive performance of each measure among an independent
validation set of events. Table 3 contains the c-statistic for each of the 11 laboratory
measures. Using only the baseline covariates of age, sex, race, and vintage, the c-statistic
was 0.541 − suggesting minimal predictive value based off these baseline characteristics
alone. Of the five laboratory measures that met the suggested criteria, four had a significant
(p < 0.05) improvement in their c-statistics, with albumin, hemoglobin and white blood
cell showing the best discrimination. Conversely, of the six measurements that did not
meet our criteria none yielded a significant improvement in discrimination.
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WHITE BLOOD CELL CT **
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Figure 3: Trajectory of laboratory measures preceding an MI.
**Five of the 11 markers (albumin [a], hemoglobin [f], iron saturation [g], platelet-count
[i], and white blood cell count [k]) show clinically meaningful changes before an MI.
5 Discussion
In this paper we suggest a straightforward procedure to detecting clinically meaningful
markers of an impending clinical event within an EHR. The irregular and longitudinal
nature of the data can make analyzing EHRs challenging. While some theoretical work
has been developed to address these challenges, these methods are not all readily accessible.
Instead, we suggest an approach that utilizes regular statistical methods and software.
The two steps in such an analysis are to first appropriately select a study sample from
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the EHR and second to analyze the data. To select the cohort, we utilized a nested case-
control study. In such a design, one identifies cases from the EHR and selects a suitable
sample of controls. One of the challenges in EHR data is identifying a time 0 for all patients,
since one can sample within calendar time or disease time. We chose to sample on calendar
time and condition on disease time. Others have used nested case-control designs noting
both their suitability and advantages for prediction with EHR data (Irizarry et al., 2012;
Wu et al., 2010).
Using the proposed mixed model with spline basis functions we illustrate a variety of
analytic questions one can ask to asses the clinical utility of a laboratory measure. These
include: Do those that experience the event show a different pattern over time? Are the
laboratory measures linear over time among the controls and non-linear among the cases?
How far out can we detect non-linearity in the cases? Undoubtedly, given a specific clinical
question one could imagine that different comparisons could be drawn. We consider this
flexibility to be one of the strengths of the proposed procedure. For example, if it were
known that a laboratory measure changed via circadian rhythms (e.g. blood pressure) and
was continuously measured over a single day, stability for controls could be proposed to
have a sinusoidal pattern.
We assessed this approach using data from an EHR system of patients undergoing
hemodialysis. We identified 4,769 people with an incident myocardial infarction and ab-
stracted 11 regular laboratory measures over a 6 month period before the event. Of the 11
measure, 5 met our criteria. We evaluated the results both qualitatively via visualization
and quantitatively through fitting a prediction model on an independent set of data. Four
of the measurements showed strong utility as a predictor, with the three most promising
measures for assessing risk of MI were a drop in albumin and hemoglobin and a rise in
white blood cell count. Not surprisingly these markers have previously been associated
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with risk of MI (Djousse et al., 2002; Friedman et al., 1974; Bassand et al., 2010). While
we have focused here on outpatient HD, we note that there are many other comparable
scenarios within typical hospital settings where patients get serial measurements, such as
inpatient Intensive Care Units, monitoring during surgery, and cancer treatment where
this approach should also prove useful.
The primary limitation is that the analytic model is a retrospective model. Once
suitable markers are identified it is of interest to predict the probability of the event given
a set of measurements. In this case, methods that estimate model (2) are necessary. For this
reason, we ultimately consider this a useful screening procedure to select markers to track
either quantitatively through algorithms embedded in the EHR predicting the probability
of an event or more qualitatively through clinical observation. With that in mind, we note
that of the five successfully identified markers, four showed significant predictive utility.
Moreover, none of the markers that were not identified showed predictive utility.
Overall, we illustrate an analytic approach to detecting laboratory measures that are
clinically meaningful markers of an impending clinical event. The appeal of this procedure
is its simplicity and intuitiveness and the use of standard statistical methodology and
theory. We believe this approach is easily transferable to analyzing other types of serially
collected EHR data that may be changing over time.
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6 Appendix
The following is R code for calculating a truncated power spline basis:
tps <- function(X, knots){
k <- length(knots)
b <- matrix(NA, nrow = length(X), ncol = k + 1)
b[,1] <- X ###Add X to basis; no intercept
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for(i in 1:k){
tp <- (X - knots[i])^3 ###Cubic polynomial
tp <- ifelse(tp > 0, tp, 0) ###Truncate
b[,(i+1)] <- tp
}
return(b)
}
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